19 August 2024
19 August 2024
The FDA approval of Imfinzi in this indication comes a month after the agency called for an overhaul of perioperative lung cancer trials.
Bavarian Nordic aims to gain a label expansion for adolescents in Europe in Q4 this year, whilst it prepares a trial in children in Africa.
While the vaccine demonstrated high responses for neutralizing influenza A titers, it failed to show sufficient efficacy against influenza B.
The Phase III inMIND trial evaluating Monjuvi as a combination treatment in relapsed/ refractory follicular lymphoma met its primary endpoint.
The FDA has granted accelerated approval for LIVDELZI to treat PBC in adults.
The $3.2bn deal was initially agreed upon by the companies in July 2024.
ENHERTU is developed by Daiichi Sankyo and co-commercialised with AstraZeneca.
SciSparc is entitled to receive Polyrizon securities valued at $3m, along with potential milestone payments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
Give your business an edge with our leading industry insights.
